Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hormone replacement therapy guideline

Executive Summary

Short-term hormone replacement therapy may not be as risky as once thought, according to an updated position statement by the North American Menopause Society. The new analysis, published in NAMS' online journal Menopause, says the risks and benefits of hormone replacement therapy change as women age. Authors say the therapy remains a viable option for the short-term treatment of moderate-to-severe vasomotor symptoms in recently menopausal women. However, women at increased risk for cardiovascular disease or breast cancer should avoid hormone therapy. The updated position statement will likely come as good news to Wyeth, which is still rebounding from a Women's Health Initiative study linking its Prempro product to increased risk of myocardial infarction, stroke and breast cancer (1"The Pink Sheet" Oct. 9, 2006, p. 8)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel